Loughborough University The Centre for Biological Engineering Doc Ref: FS008.1 : HTA-PR-FORM/007 Acquisition and Receipt of Biological Materials Version N°: 1.0 Issue Date:

ARF No: CBE/ARF/000 3

PART A: To be completed by the	Receiver (a separate	form must be	completed for	each sample	type)		
A1. Details of Sample/Specimen								
Type/ID: (eg primary cell, cell line, tissufluid, excreta, biological agent)	Haematopoietic Cell based Therapies					⊠Human		
Format / Quantity: (eg vials, slides, e	etc) 2x	2x50mL tube containing 20mL ficol unit						
Tissue site/Organ source:	Co	Cord Blood					□N/A	
Batch N°:								
Is the sample/specimen considered to be Relevant Material under the Human Tissue Act (HTA)? If No, go to section A2.							⊠Yes □No	
Is the material obtained from an HTA licenced Tissue Bank with REC approval for generic research use?						use?	⊠Yes □No	
Is the material obtained for storage and use under a project specific NHS REC approval?							□Yes □No	
Is the material licensable under the HTA? <i>Indicate source below:</i>							⊠Yes □No	
☑HTA licensed organisation ☑C	Commercia	l Supplier[☐ Imported (fro	om outside Eng	land, Wales o	r N.Ireland)		
If Yes, list lot numbers (or other identifier) & the corresponding assigned unique sample ID		Lot N°: POOL 64 219201701 & 02 processed to 1 x cryovial containing 4.6e6 cells			Assigned Unique ID (Procuro): S00076941			
If Yes, provide Project Ref N°: BRA060 & BR			RA010					
If Yes, provide the name of the PI: Dr Rob			r Rob Thomas					
A2. Details of Receipt								
Date/Time of receipt	Da	ate	21/09/2017		Time:	e 29		
ID of Receiver	N	ame:	Jon Harriman		Dept:	СВЕ		
ID of Supplier/Provider	N	ame:	Anthony Nolan		Country:	UK		
PART B: To be completed by the	Receiver						4 16 15	
B1. Inspection and Quarantine								
Has a biological risk assessment for the use of this material been approved?		of this	⊠Yes □No	Ref Number: BRA060 & BRA010				
Physical integrity of the material(s) acceptable?		ble?	⊠Yes □No	If No, describ	oe action taken			
Quantity received correct?			⊠Yes □No	If No, describ	describe action taken			
Labelling correct and legible?			⊠Yes □No	If No, describe action taken				
Is the relevant documentation attached to this form? If No, add reference or details to ensure traceability	C of A or quality	equivalent	evidence of	⊠Yes □No □N/A				
	Agreeme	nts to enak	ole transfer of A	⊠Yes □No □N/A				
	Details/evidence/assurance of consent			⊠Yes □No □N/A				

Other (describe))	□Yes □No □N/A			
Temporary storage - Quarantine location (as applicable)	Building/Room		CBE H19 Cold store & once processed will be stored in - 80 overnight and transferred to Liquid N2 - Bank 7			
	Storage Unit ID		4Fri-HTA & Cryo-HTA			
	Within storage unit location ID		Bank7 Rack2 BoxC8			
	Date/Time of quarantine 29/09/2017			* u		
Submitted by:	Signature:		Date: 30/09/2017			
PART C: To be completed by the	e departmental Q	uality Manager				
C1. Quality Assurance Checks						
Has the sample/specimen been	☐Yes ☐No ☐N/A					
Has the donor been screened fo	□Yes □No □N/A					
Has the sample/specimen been	□Yes □No □N/A					
Is there evidence that the suppli or other recognised certification	□Yes □No □N/A					
For HTA licensable material, is the and use of the material under the	□Yes □No □N/A					
Is there sufficient evidence to su	□Yes □No □N/A					
C2. Approval for release from q	uarantine			1		
Can the material be released fro released for processing?	m quarantine and	I transferred to desi	gnated storage area or	☑Yes □No		
		☐Accept as is, b	ut with extra controls			
If No, provide recommendations for deposition of the material and the results of any action relating to non-conforming material.		☐Rework or rep specified require	rocess to meet the ments			
		☐Test to meet s	pecified requirements	-		
relating to non-comorning mate		☐Return to supp	olier/provider			
		□Disposal				
If Yes, provide details of storage applicable)		Building/Room				
		Storage Unit ID		,		
	location (as	Within storage unit location ID		Bank 7 RACK 2 BOXC		
		Database Refere	nce	,		
	Date/Time of tran		nsfer			
Approved by:		Signature:		Date: 4/10/17		